
Merck granted EC approval for adult-specific pneumococcal vaccine Capvaxive
Merck & Co – known as MSD outside the US and Canada – has announced that its adult-specific 21-valent pneumococcal conjugate vaccine has been approved by the European Commission (EC). The vaccine, marketed under the brand name Capvaxive, has been …